Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?

Cleve Clin J Med. 2023 Oct 2;90(10):607-609. doi: 10.3949/ccjm.90a.23004.

Authors

Richard Sekerak¹, Johanna Ben-Ami Lerner², Pooja Prasad³, Megha Prasad⁴

Affiliations

¹ Columbia University Medical Center, New York, NY ris9105@nyp.org.
² NYU Langone, New York, NY.
³ Oregon Health Science University, Portland, OR.
⁴ Assistant Professor of Medicine, Columbia University Medical Center, New York, NY.

PMID: 37783497
DOI: 10.3949/ccjm.90a.23004

No abstract available

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Heart Failure* / drug therapy
Humans
Hypoglycemic Agents / pharmacology
Renal Insufficiency, Chronic* / complications
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents